Acer To Respond To Edsivo CRL In Ehlers-Danlos Syndrome

Although the US FDA is looking for another clinical trial of Acer Therapeutics’ potential therapy for vascular Ehlers-Danlos syndrome, there may be further discussion about the route to market in this rare condition.